Compare Torrent Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs ABBOTT INDIA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA ABBOTT INDIA TORRENT PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 59.8 44.7 133.7% View Chart
P/BV x 6.3 12.8 49.4% View Chart
Dividend Yield % 0.8 0.5 150.4%  

Financials

 TORRENT PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
ABBOTT INDIA
Mar-18
TORRENT PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,5506,110 25.4%   
Low Rs1,1443,996 28.6%   
Sales per share (Unadj.) Rs354.71,552.2 22.9%  
Earnings per share (Unadj.) Rs40.1188.8 21.2%  
Cash flow per share (Unadj.) Rs64.2196.4 32.7%  
Dividends per share (Unadj.) Rs14.0055.00 25.5%  
Dividend yield (eoy) %1.01.1 95.5%  
Book value per share (Unadj.) Rs273.1796.6 34.3%  
Shares outstanding (eoy) m169.2221.25 796.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.83.3 116.6%   
Avg P/E ratio x33.626.8 125.6%  
P/CF ratio (eoy) x21.025.7 81.5%  
Price / Book Value ratio x4.96.3 77.7%  
Dividend payout %34.929.1 119.9%   
Avg Mkt Cap Rs m227,897107,376 212.2%   
No. of employees `00014.73.3 442.5%   
Total wages/salary Rs m11,3533,937 288.4%   
Avg. sales/employee Rs Th4,083.09,929.3 41.1%   
Avg. wages/employee Rs Th772.31,185.1 65.2%   
Avg. net profit/employee Rs Th461.31,207.7 38.2%   
INCOME DATA
Net Sales Rs m60,02132,985 182.0%  
Other income Rs m2,9881,170 255.4%   
Total revenues Rs m63,00934,155 184.5%   
Gross profit Rs m13,4935,245 257.2%  
Depreciation Rs m4,086162 2,523.8%   
Interest Rs m3,08538 8,075.4%   
Profit before tax Rs m9,3106,215 149.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5292,203 114.8%   
Profit after tax Rs m6,7814,012 169.0%  
Gross profit margin %22.515.9 141.4%  
Effective tax rate %27.235.4 76.6%   
Net profit margin %11.312.2 92.9%  
BALANCE SHEET DATA
Current assets Rs m52,62322,655 232.3%   
Current liabilities Rs m52,0226,681 778.7%   
Net working cap to sales %1.048.4 2.1%  
Current ratio x1.03.4 29.8%  
Inventory Days Days12065 184.6%  
Debtors Days Days7629 261.5%  
Net fixed assets Rs m85,016835 10,175.9%   
Share capital Rs m846213 398.2%   
"Free" reserves Rs m45,37616,715 271.5%   
Net worth Rs m46,22216,928 273.1%   
Long term debt Rs m41,1150-   
Total assets Rs m142,43224,162 589.5%  
Interest coverage x4.0163.7 2.5%   
Debt to equity ratio x0.90-  
Sales to assets ratio x0.41.4 30.9%   
Return on assets %6.916.8 41.3%  
Return on equity %14.723.7 61.9%  
Return on capital %14.236.9 38.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,580369 3,956.2%   
Fx outflow Rs m3,6003,807 94.6%   
Net fx Rs m10,980-3,438 -319.4%   
CASH FLOW
From Operations Rs m8,9421,527 585.6%  
From Investments Rs m-47,070-2,148 2,190.9%  
From Financial Activity Rs m34,174-1,024 -3,336.3%  
Net Cashflow Rs m-3,655-1,646 222.1%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.0 7.9 88.9%  
FIIs % 12.6 0.1 12,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 17.1 51.5%  
Shareholders   26,511 18,270 145.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   GLENMARK PHARMA  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  DIVIS LABORATORIES  FULFORD INDIA  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS